OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)

Heymach, John V.; Negrão, Marcelo V.; Robichaux, Jacqulyne P.; Carter, B.; Patel, Ami; Altan, Mehmet; Gibbons, Don L.; Fossella, Frank V.; Simon, George R.; Lam, Vincent K.; Blumenschein, George R.; Tsao, Anne S.; Mott, Frank E.; Jenkins, David W.; Mack, David H.; Feng, Lei; Roeck, Brent; Yang, Zane; Papadimitrakopoulou, V.; Elamin, Yasir Y.

doi:10.1016/j.jtho.2018.08.243

Cited by 94 publications

(74 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poziotinib has been proven to be a potent inhibitor of both EGFR and HER2 exon 20 insertion mutations through preclinical models and clinical experience [78]. Its preliminary clinical activity has been reported in 2018 WCLC with confirmed ORR of 43% in advanced NSCLC [79]. Another novel agent for EGFR exon 20 insertion, TAK-788, has also been reported in 2018 WCLC [80].…”

Section: Poziotinib Tak-788 Afatinib and Pyrotinibmentioning

confidence: 99%

Emerging therapies for non-small cell lung cancer

et al. 2019

View full text Add to dashboard Cite

Recent advances in the field of novel anticancer agents prolong patients' survival and show a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the two major areas undergoing rapid development. Although increasing novel anticancer agents were innovated, how to translate and optimize these novel agents into clinical practice remains to be explored. Besides, toxicities and availability of these drugs in specific regions should also be considered during clinical determination. Herein, we summarize emerging agents including tyrosine kinase inhibitors, checkpoint inhibitors, and other potential immunotherapy such as chimeric antigen receptor T cell for non-small cell lung cancer attempting to provide insights and perspectives of the future in anticancer treatment.

show abstract

Section: Poziotinib Tak-788 Afatinib and Pyrotinibmentioning

confidence: 99%

Emerging therapies for non-small cell lung cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Another therapy in development, poziotinib, has also shown potential for patients with EGFR exon 20 insertions, according to findings presented at the IASLC 19th World Conference on Lung Cancer. This therapy induced a confirmed ORR of 43% among evaluable patients with EGFR exon 20 mutant NSCLC [2].…”

Section: Egfr: Uncommon Mutations-potential Targeted Treatment For Exmentioning

confidence: 74%

Targeted therapy in lung cancer—ASCO 2019 update

Wass

Lang

Lamprecht

et al. 2019

memo

View full text Add to dashboard Cite

New targeted therapies for patients with non small cell lung cancer were presented at this year's ASCO. EGFR exon 20 insertions might soon be treatable with TAK-788, which showed an objective response rate (ORR) of between 25 and 56% with a disease control rate (DCR) between 67 and 100% depending on the presence or absence of brain metastases at baseline. Capmatinib and tepotinib showed durable responses in MET exon 14 mutations as presented in the phase II GEOMETRY trial and the VISION trial. The median duration of response (DOR) was 9.7 months with a median progression free survival (PFS) of 5.42 months in pretreated patients and 11.14 months respective 9.6 months in those receiving capmatinib in the frontline setting. Tepotinib showed similar results with a median DOR of 12.4 months and a DCR of 66.7%. For RET-fusion lung cancer the well tolerated RET inhibitor BLU-667 has already been granted breakthrough therapy designation. Among previously treated patients an ORR of 58% and a DCR

show abstract

“…The primary results of clinical trial NCT03318939 showed that the patients with HER2 mutation are predicted to bene t from pozitinib. [10,11] Gene fusion, especially kinase gene fusion, is another uncommon mutation type in lung cancer. For example, anaplastic lymphoma kinase (ALK), ROS proto-oncogene receptor tyrosine kinase 1 (ROS1), and rearranged during transfection proto-oncogene gene (RET) are known to have fusion mutations, which account for 2-7%, 1-2%, and 1-2%of advanced NSCLC patients, respectively.…”

Section: Introductionmentioning

confidence: 99%

Pathological Signature and Therapeutic Status of NSCLC Patients with Common or Rare Driver Gene Alterations in North China：A real world retrospective study

Zhang

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Although guidelines recommended to test EGFR/ALK/ROS-1 gene alterations in advanced non-small cell lung cancer (NSCLC) patients before treatment, there is now growing evidence that rare driver genes and mutations also can inform targeted therapy and improve outcomes for this traditionally underrepresented population. This study aimed to describe mutational patterns and linked clinical parameters in a Chinese population-based NSCLC cohort.Methods: This study included patients with pathologically confirmed NSCLC, who were routinely screened for EGFR, KRAS, BRAF, ALK, ROS1, RET, MET, HER2, and PIK3CA mutations by the NMPA approved multi-gene detection kit. The demographic and clinicopathological data, treatment information, clinical outcomes after first-line treatment, as well as nine driver gene mutation statuses and PD-L1 expression level of these patients were retrospectively collected.Results: Finally, 431 patients were enrolled, most patients were male (55.9%), with adenocarcinoma or adenosquamous carcinoma (80.7%) and in stage IV (50.6%). Among all the 431 patients, 61.5% patients were identified with gene mutation including 101 with rare mutation, 164 with 19del or with L858R mutation. Adenocarcinoma patients have a higher mutation rate (73.6%), and the mutations mainly occur in EGFR, KRAS, ALK and HER2. While, the gene mutation characteristics in squamous cell carcinoma patients with were relatively simple, only 2 patients with EGFR 19del and 2 patients with PIK3CA mutation. More PD-L1 expression could detected in patients with rare mutation. The median PFS1 of patients with common mutation (13 months, 95% CI: 9.9-16) was longer than the patients with rare mutation (5 months, 95 % CI: 0-10.5). Conclusions: The clinicopathologic features and clinical treatment status among NSCLC patients with common or rare driver gene mutations were different. The survival of patients with rare mutation was worse than that of patients with common mutation. Therefore, more attention should be paid to the treatment strategy and survival status of patients with rare mutations in clinical practice.

show abstract

OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)

Cited by 94 publications

References 0 publications

Emerging therapies for non-small cell lung cancer

Emerging therapies for non-small cell lung cancer

Targeted therapy in lung cancer—ASCO 2019 update

Pathological Signature and Therapeutic Status of NSCLC Patients with Common or Rare Driver Gene Alterations in North China：A real world retrospective study

Contact Info

Product

Resources

About